

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>EVNIN LUKE</u> (Last) (First) (Middle) <u>C/O MPM BIOIMPACT LLC</u> <u>399 BOYLSTON STREET, SUITE 1100</u> (Street) <u>BOSTON MA 02116</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Werewolf Therapeutics, Inc. [HOWL]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>06/04/2026</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/04/2026		S ⁽¹⁾		20,072 ⁽²⁾	D	\$0.44 ⁽³⁾	462,704	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock	06/05/2026		S ⁽¹⁾		24,946 ⁽⁶⁾	D	\$0.4 ⁽⁷⁾	437,758	I	See Footnotes ⁽⁴⁾⁽⁸⁾
Common Stock	06/08/2026		S ⁽¹⁾		60,547 ⁽⁹⁾	D	\$0.4 ⁽¹⁰⁾	377,211	I	See Footnotes ⁽⁴⁾⁽¹¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date					
					Code	V	(A)	(D)	Title	Amount or Number of Shares			

Explanation of Responses:

- Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
- The shares were sold as follows: 2,150 by MPM Asset Management LLC ("AM LLC"), 13,578 by MPM BioVentures 2014, L.P. ("BV 2014"), 906 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 467 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,971 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$0.43 to \$0.4499 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- The shares are held as follows: 49,573 by AM LLC, 313,005 by BV 2014, 20,875 by BV 2014(B), 10,771 by AM BV2014 and 68,480 by MPM OIF.
- The shares were sold as follows: 2,673 by AM LLC, 16,874 by BV 2014, 1,126 by BV 2014(B), 581 by AM BV2014 and 3,692 by MPM OIF.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$0.3918 to \$0.454 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares are held as follows: 46,900 by AM LLC, 296,131 by BV 2014, 19,749 by BV 2014(B), 10,190 by AM BV2014 and 64,788 by MPM OIF.
- The shares were sold as follows: 6,487 by AM LLC, 40,957 by BV 2014, 2,732 by BV 2014(B), 1,410 by AM BV2014 and 8,961 by MPM OIF.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$0.3706 to \$0.4126 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares are held as follows: 40,413 by AM LLC, 255,174 by BV 2014, 17,017 by BV 2014(B), 8,780 by AM BV2014 and 55,827 by MPM OIF.

/s/ Luke Evnin

06/08/2026

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

**** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).**

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.